DOI QR코드

DOI QR Code

Ginsenoside Rh2 differentially Mediates microRNA Expression to Prevent Chemoresistance of Breast Cancer

  • Wen, Xu (Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province) ;
  • Zhang, He-Da (Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province) ;
  • Zhao, Li (Anhui University of Chinese Medicine) ;
  • Yao, Yu-Feng (Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province) ;
  • Zhao, Jian-Hua (Department of Center of Clinical Laboratory Science, the Affiliated Jiangsu Cancer Hospital, Nanjing Medical University) ;
  • Tang, Jin-Hai (Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province)
  • Published : 2015.03.04

Abstract

Chemoresistance is the most common cause of chemotherapy failure during breast cancer (BCA) treatment. It is generally known that the mechanisms of chemoresistance in tumors involve multiple genes and multiple signaling pathways,; if appropriate drugs are used to regulate the mechanisms at the gene level, it should be possible to effectively reverse chemoresistance in BCA cells. It has been confirmed that chemoresistance in BCA cells could be reversed by ginsenoside Rh2 (G-Rh2). Preliminary studies of our group identified some drugresistance specific miRNA. Accordingly, we proposed that G-Rh2 could mediate drug-resistance specific miRNA and corresponding target genes through the gene regulatory network; this could cut off the drug-resistance process in tumors and enhance treatment effects. G-Rh2 and breast cancer cells were used in our study. Through pharmaceutical interventions, we could explore how G-Rh2 could inhibit chemotherapy resistance in BCA, and analyze its impact on related miRNA and target genes. Finally, we will reveal the anti-resistance molecular mechanisms of G-Rh2 from a different angle in miRNA-mediated chemoresistance signals among cells.

Keywords

Breast cancer;chemoresistance;G-Rh2;miRNA;cell

Acknowledgement

Supported by : Natural Science Foundation

References

  1. An IS, An S, Kwon KJ, et al (2013). Ginsenoside Rh2 mediates changes in the microRNA expression profile of human nonsmall cell lung cancer A549 cells. Oncol Rep, 29, 523-8.
  2. Chan LS, Yue PY, Wong YY, et al (2013). MicroRNA-15b contributes to ginsenoside-Rg1-induced angiogenesis through increased expression of VEGFR-2. Biochem Pharmacol, 86, 392-400. https://doi.org/10.1016/j.bcp.2013.05.006
  3. Chen X, Liang H, Zhang J, Zen K, Zhang CY (2012). Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol, 22, 125-132. https://doi.org/10.1016/j.tcb.2011.12.001
  4. Choi S, Oh JY, Kim SJ (2011). Ginsenoside Rh2 Induces Bcl-2 family proteins-mediated apoptosis in vitro and in xenografts in vivo models. J Cell Biochem, 112, 330-340. https://doi.org/10.1002/jcb.22932
  5. Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of Loubo$^{(R)}$ (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7. https://doi.org/10.7314/APJCP.2013.14.1.413
  6. Kutanzi KR, Yurchenko OV, Beland FA (2011). MicroRNAmediated drug resistance in breast cancer. Clin Epigenetics, 2, 171-185. https://doi.org/10.1007/s13148-011-0040-8
  7. Jiao X, Zhao L, Ma M, et al (2013). MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat, 39, 717-730.
  8. Li XJ, Ji MH, Zhong SL, Tang JH (2012). MicroRNA-34a modulates chemosensitivity of breast cancer cells to Adriamycin by targeting Notch1. Arch Med Res, 43, 514-521. https://doi.org/10.1016/j.arcmed.2012.09.007
  9. Z HH, PM, DW, Xin JX, et al (2014). MiR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep, 31, 1473-39.
  10. Chakraborty S, Mazumdar M, Mukherjee S, et al (2014). Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett, 588, 549-59. https://doi.org/10.1016/j.febslet.2013.11.040
  11. Gong JP, Yang L, Huang XE, et al (2014). Outcomes based on risk assessment of anastomotic leakage after rectal cancer surgery. Asian Pac J Cancer Prev, 15, 707-12. https://doi.org/10.7314/APJCP.2014.15.2.707
  12. Hamada S, Masamune A, Miura S, Satoh K, et al (2014). MiR- 365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal, 26, 179-185. https://doi.org/10.1016/j.cellsig.2013.11.003
  13. Ha S, Masa A, Miura S, Satoh K (2014). MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal, 26, 179-85. https://doi.org/10.1016/j.cellsig.2013.11.003
  14. Liu YC, Zhou SB, Gao F, et al (2013). Phase II study on breast conservative surgery plus chemo- and radiotherapy in treating Chinese patients with early stage breast cancer.Asian Pac J Cancer Prev, 14, 3747-50. https://doi.org/10.7314/APJCP.2013.14.6.3747
  15. Man M, Kari A, Ban M, Ka B (2013). Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer. Pathol Oncol Res, 14, 1-11.
  16. Ratert N, Meyer HA, Jung M, et al (2013). miRNA profiling identifies candidate miRNAs for bladder cancer diagnosis and clinical outcome. J Mol Diagn, 15, 695-705. https://doi.org/10.1016/j.jmoldx.2013.05.008
  17. Wang L, Huang XE, Cao J (2014). Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Asian Pac J Cancer Prev, 15, 5597-600. https://doi.org/10.7314/APJCP.2014.15.14.5597
  18. Wu N, Wu GC, Hu R, et al (2011). Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin, 32, 345-53. https://doi.org/10.1038/aps.2010.220
  19. Zhang L, Zhang Y (2013). Halothane increases neuronal cell death vulnerability by downregulating miR-214 and upregulating Bax. Int J Clin Exp Med, 6, 452-60.
  20. Zhang J, Zhou F, Wu X, et al (2012). Cellular pharmacokinetic mechanisms of Adriamycin resistance and its modulation by 20 (S)-ginsenoside Rh2 in MCF-7/Adr cells. Br J Pharmacol, 165, 120-34. https://doi.org/10.1111/j.1476-5381.2011.01505.x
  21. Zhang J, Lu M, Zhou F, et al (2012). Key role of nuclear factor-B in the cellular pharmacokinetics of adriamycin in MCF-7/ adr cells: the potential mechanism for synergy with 20 (S)-ginsenoside Rh2. Drug Metab Dispos, 40, 1900-8. https://doi.org/10.1124/dmd.112.045187
  22. Zhong S, Li W, Chen Z, Tang JH (2013). MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene, 15, 8-14.

Cited by

  1. A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer vol.17, pp.3, 2015, https://doi.org/10.1093/bib/bbv053
  2. Highly efficient biotransformation of ginsenoside Rb1 and Rg3 using β-galactosidase from Aspergillus sp. vol.5, pp.96, 2015, https://doi.org/10.1039/C5RA11519A
  3. Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1 vol.37, pp.5, 2016, https://doi.org/10.3892/ijmm.2016.2539
  4. Ginsenoside Rh2 inhibits proliferation and induces apoptosis in human leukemia cells via TNF-α signaling pathway vol.48, pp.8, 2016, https://doi.org/10.1093/abbs/gmw049
  5. New generation of drug delivery systems based on ginsenoside Rh2-, Lysine- and Arginine-treated highly porous graphene for improving anticancer activity vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-017-18938-y
  6. Microarray analysis of altered long non-coding RNA expression profile in liver cancer cells treated by ginsenoside Rh2 pp.1477-2213, 2018, https://doi.org/10.1080/10286020.2018.1490273
  7. Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives vol.8, pp.52, 2018, https://doi.org/10.1039/C8RA04879G
  8. Research Progress on Reversing Multidrug Resistance in Tumors by Using Chinese Medicine vol.24, pp.6, 2018, https://doi.org/10.1007/s11655-018-2910-1